JAZZ vs. ZTS: Jazz Pharmaceuticals vs. Zoetis Stock Comparison
How do Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
| Profile Item | JAZZ | ZTS |
|---|---|---|
| Name | Jazz Pharmaceuticals plc | Zoetis Inc. Class A Common Stock |
| Country/Region | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 15.07 billion USD | 32.26 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2007 | February 1, 2013 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | JAZZ | ZTS |
|---|---|---|
| Total Return (1Y) | 84.44% | -30.10% |
| Total Return (3Y, Annualized) | 27.57% | -20.42% |
| Total Return (5Y, Annualized) | 12.88% | -16.87% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | JAZZ | ZTS |
|---|---|---|
| Volatility (1Y, Annualized) | 38.74% | 38.23% |
| Beta (5Y) | 0.33 | 0.66 |
| Max Drawdown (5Y) | -42.03% | -70.45% |
| Avg. Volume (3M) | 878.80K | 4.65M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | JAZZ | ZTS |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | -0.90 |
| Sortino Ratio (1Y) | 4.14 | -1.10 |
Profitability
ROE (TTM)
Zoetis (ZTS) at 57.63% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for ZTS.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
57.63%
- Max
- 109.18%
- ZTS
- 57.63%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Zoetis (ZTS) at 26.41% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.41%
- ZTS
- 26.41%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.19%
- Max
- 83.12%
- ZTS
- 38.19%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | JAZZ | ZTS |
|---|---|---|
| ROE (TTM) | 5.05% | 57.63% |
| ROA (TTM) | 6.92% | 14.87% |
| Net Margin (TTM) | 4.37% | 26.41% |
| Operating Margin (TTM) | 30.17% | 38.19% |
| Gross Margin (TTM) | 91.10% | 71.65% |
Growth
Revenue Growth
Both Jazz Pharmaceuticals (JAZZ) at 4.88% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Zoetis (ZTS) at 10.05% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | JAZZ | ZTS |
|---|---|---|
| Revenue Growth (YoY) | 4.88% | 2.28% |
| Revenue Growth (3Y CAGR) | 5.26% | 5.42% |
| EPS Growth (YoY) | -167.51% | 10.05% |
| EPS Growth (3Y CAGR) | -- | 10.27% |
Financial Strength
Current Ratio (MRQ)
Both Jazz Pharmaceuticals (JAZZ) at 1.82 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ZTS
- 2.35
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but ZTS is more stretched: Jazz Pharmaceuticals (JAZZ) at 1.35 sits in the higher-leverage quartile and Zoetis (ZTS) at 2.80 is above its industry benchmark range.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.80
- ZTS
- 2.80
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | JAZZ | ZTS |
|---|---|---|
| Current Ratio (MRQ) | 1.82 | 2.35 |
| Debt / Equity (MRQ) | 1.35 | 2.80 |
| Net Debt / EBITDA | 1.39 | 1.92 |
Dividends
Dividend Yield (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.55%
- ZTS
- 2.55%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.24%
- ZTS
- 35.24%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | JAZZ | ZTS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.55% |
| Dividend Payout Ratio (TTM) | 0.00% | 35.24% |
Valuation
P/E Ratio (TTM)
Zoetis (ZTS) at 13.50 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.50
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- ZTS
- 13.50
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.40
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ZTS
- 3.40
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Jazz Pharmaceuticals (JAZZ) at 3.59 is valued about in line with its industry on P/B ratio, while Zoetis (ZTS) at 9.80 carries an above-peer premium to book — ZTS is pricier on assets.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.80
- Max
- 13.53
- ZTS
- 9.80
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | JAZZ | ZTS |
|---|---|---|
| P/E Ratio (TTM) | 69.46 | 13.50 |
| P/S Ratio (TTM) | 3.19 | 3.40 |
| P/B Ratio (MRQ) | 3.59 | 9.80 |
| Free Cash Flow Yield (TTM) | 11.16% | 6.36% |